News | May 29, 2007

Optimizer Heart Failure Device Implanted at Tennessee Facility

May 30, 2007 — Cardiovascular Associates, Kingsport, TN, has announced the successful implant of a new investigational cardiac medical device called the Optimizer for the treatment of heart failure.

The Optimizer, made by Impulse Dynamics, is an implantable pulse generator that delivers electrical impulses to the heart for patients who suffer from moderate-to-severe heart failure. This procedure was performed at Holston Valley Medical Center, Heart Institute on Wednesday, May 23rd.

"Congestive heart failure (CHF) is a major health problem in the U.S. and world wide,” said Gregory Jones, M.D., principal investigator of the study. “Despite significant improvement in mortality and symptoms from heart failure with pharmacologic treatment, many patients remain incapacitated by their CHF. This therapy is a novel treatment using electrical stimuli delivered to the heart in an effort to improve contractility (forcefulness of the heart beat). This in turn can hopefully improve the functional capacity of the patient and reduce some of their symptoms."

There are currently no other devices that provide the same effect as the Optimizer. Pacemakers work to re-establish a normal heart rate through the administration of electrical pacing signals. Defibrillators work to stop abnormal rhythms in a heart that is beating chaotically or too fast by delivering an electric shock. While these devices intend to resolve problems with the heart's rhythm, the Optimizer System is designed to modulate the strength of contraction of the heart muscle rather than its rhythm.

The underlying technology of the device is Cardiac Contractility Modulation, or CCM, a method for treating failing hearts. Unlike signals generated by other cardiac devices, the CCM signals do not initiate a heartbeat. Rather, CCM signals are intended to modify heart cell function in a manner that affects the contractility of the heart muscle.

For more information visit www.impulsedynamics.com.

Related Content

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
Overlay Init